Sign up to our newsletter Subscribe
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.